HER2 Testing in Breast Cancer: Opportunities and Challenges

Publisher： Karger

E-ISSN： 1661-3805|1|2|69-76

ISSN： 1661-3791

Source： Breast Care, Vol.1, Iss.2, 2006-05, pp. : 69-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy Standards in HER2-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-11 ,pp. : 418-422

Karger

Access to resources Recommend Favorite

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 392-397

Karger

Access to resources Recommend Favorite

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 424-426

Karger

Access to resources Recommend Favorite

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite